PubMed Health⌕ Search

Biomedical subjects

A R Schned

Publications and source records attributed to A R Schned.

At least 19 recordsLinked to original sources

Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter.

Matrix metalloproteinase-1 (MMP-1, collagenase-1), which degrades interstitial collagen, is expressed at high levels by some tumor cells and is thought to enhance their invasiveness and metastatic potential. We recently described a common single nucleotide insertion polymorphism (2G allele) at -1,607 bp in the promoter of the MMP-1 gene that creates a binding site for the ETS family of transcription factors, and that is associated with enhanced transcription of this gene and increased enzyme activity. Allelic loss at the MMP-1 locus on chromosome 11 occurs in many tumors including melanoma, an invasive and aggressive cancer. We hypothesized that although loss of either the 1G or 2G allele from 1G/2G heterozygotes is random, retention of the transcriptionally more active 2G allele would favor tumor invasion and metastasis. As a result, a higher proportion of metastases would contain the 2G genotype than the 1G genotype. We report here the development of quantitative methods for assessing allelic loss at the MMP-1 locus, and demonstrate that 83% of the metastatic melanomas with loss of heterozygosity at this locus retained the 2G allele. This supports the hypothesis that retention of the 2G allele favors tumor invasion and metastasis in melanoma.

Adult↗

A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.

PURPOSE: The clinical observation of spontaneous regression in patients with renal cell carcinoma (RCC) and the response to various immunotherapeutic therapies strongly suggest a role for the host immune system in this disease. Prior studies showed that sequential administration of interferon (IFN) gamma and IFN alpha to RCC patients was safe. Clinical responses as well as immune changes in the peripheral blood mononuclear cell compartment were observed. Autologous tumor cell vaccines (AV) have also demonstrated activity in renal cell carcinoma. We hypothesize that the addition of AV to sequential IFN gamma and a therapy might improve the tumor-specific immune response by providing an appropriate source of antigen in the appropriate cytokine environment. To our knowledge, this is the first trial using AV combined with IFN alpha and IFN gamma. The purpose of this study was to evaluate the feasibility of manufacturing and administering (AV) from resected tumor samples, and administration of AV with combination IFN gamma and IFN alpha therapy. Finally, the impact on immunological parameters of these treatment options was assessed. MATERIALS AND METHODS: Patients with metastatic RCC were randomly assigned to receive AV plus bCG along with a sequential administration of IFN gamma and a either together or after initiation of vaccine. Toxicity and clinical responses were evaluated. Modulations of the immune system were investigated by analyzing phenotype, cytokine mRNA expression, T cell proliferation and cytotoxicity in the peripheral blood mononuclear cell compartment. RESULTS: Fourteen patients with metastatic renal cell carcinoma were enrolled in this study; 9 were available for response evaluation. In a 70 day period, 3 (33%) showed mixed responses, 5 (56%) stable disease and 1 (11%) progression of disease. Toxicities were consistent with previous clinical reports. In the flow-cytometry phenotype analysis, stimulation of distinct subsets of circulating T-lymphocytes and a decrease of CD8+ T cell subsets was demonstrated. T-cell proliferation to allogeneic tumor cell stimulation improved following treatment. IL-4 and IL-5 mRNA levels were reduced in all patients after treatment. Patients who responded to treatment did not produce any IL-4 mRNA at all, before or after treatment. CONCLUSIONS: AV with IFNgamma and IFNalpha therapy might induce a MHC class-mediated cytotoxic T lymphocyte (CTL) response. We suggest that adequate therapy might direct T cell response toward a Th1 type response. We hypothesize a state of improved immune readiness in patients who might eventually respond to immunotherapy.

Adult↗

In vivo description of dendritic cells in human renal cell carcinoma.

PURPOSE: Dendritic cells (DCs) are efficient and effective antigen-presenting cells that play a major role in initiating the primary immune response. They are the most potent stimulators of T-cell activation and would thus be expected to be of great importance in the antitumoral immune response. Although DC phenotype and function have been described under in vitro conditions, their in vivo characteristics are less well detailed. Human renal cell carcinoma (RCC) is an excellent model to explore tumor infiltrating dendritic cells (TiDCs) because of rare clinical spontaneous regressions and the association of high numbers of tumor infiltrating lymphocytes (TiLs), suggesting a strong immune response. MATERIALS AND METHODS: We determined the in situ phenotype of mature CD83+ TiDCs using monoclonal antibodies to known activation molecules (CD86 [B7.2], CD80 [B7.1], CD40, CD54, CD1a and HLA-DR). Seventeen primary RCCs, representing four distinct histologies, were evaluated using double-staining immunohistochemical techniques and light microscopy. RESULTS: CD83+ TiDCs were found in all tumors. Expression of CD40 correlated with expression of CD1a on CD83+ TiDCs. Expression of CD54 (ICAM-1) correlated with a lower expression of CD86 (B7.2) as well as a decrease in CD3+ and CD8+ TiLs. CONCLUSIONS: These data suggest a de novo lipid or sugar-based immunogenic antigen presentation by TiDCs. Also, the data support an impaired antigen-presenting capability for CD54+ TiDCs based on the decreased coexpression of CD86 (B7.2) and the decrease of associated CD8+ TiLs.

Antigens, CD↗

Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma.

The functional expression of Fas-ligand on tumor cells reported in a variety of neoplasms has been proposed by several groups as a mechanism of tumor escape from immunological detection. To better support this hypothesis, we have evaluated and quantified for the first time the presence of the Fas(CD95)-R molecule on tumor-infiltrating lymphocytes and on matched peripheral blood lymphocytes (PBLs) of renal cell cancer patients. By two-color flow cytometry we have detected a significant increase in the Fas(CD95)-R expression on tumor-infiltrating lymphocytes compared with matched patient and normal volunteer PBLs. We also observed a decreased expression of the Fas(CD95)-R expression on PBLs from renal cell cancer patients compared with normal healthy controls. The Fas(CD95)-R expression was observed predominantly on the CD4+ subset in all three groups. These different distributions of the Fas(CD95)-R molecule support the hypothesis that the Fas(CD95)-R/Fas(CD95)-L pathway and tumor microenvironment play a major role in the modulation of T-cell function and differentiation to either memory and activation or apoptosis.

Antigens, Neoplasm↗

Neoadjuvant androgen ablation for localized prostatic cancer: pathology methods, surgical end points and meta-analysis of randomized trials.

PURPOSE: At least 7 centers or collaborative groups have performed randomized clinical trials of neoadjuvant androgen ablation and radical prostatectomy versus radical prostatectomy alone for localized prostatic cancer. Our objectives were to analyze treatment results in terms of 2 standard outcome measures, to identify patient characteristics and other factors that explain outcome differences between trials, and to use pooled data to test the hypothesis that neoadjuvant treatment alters outcomes. MATERIALS AND METHODS: Trials were identified by MEDLINE search and review of published bibliographies, and examined for pathological techniques used to assign surgical end points. An attempt was made to contact trial group members for clarification and updated information. The resulting data were transformed as needed into standardized end points of pT stage and negative surgical margin. A series of contingency tables were used to study relationships between treatment outcomes and various risk factors. RESULTS: In addition to neoadjuvant treatment, numerous risk factors related to treatment regimen and patient characteristics apparently influenced treatment outcome, and should be reanalyzed when future followup trial data become available. CONCLUSIONS: In radical prostatectomy there is a need for uniform ways to process specimens, assign surgical stage and establish standardized surgical end points. Despite differences in risk factors, the trials were similar in overall design. Within these constraints neoadjuvant androgen ablation was significantly associated with low pT stage and negative surgical margin. Longer followup is needed to validate these measures as good surrogates for tumor specific survival.

Aged↗

Histological evaluation of the testicular nubbin in the vanishing testis syndrome.

PURPOSE: We reviewed histopathological studies of the testicular nubbins associated with the vanishing testis syndrome, and determined whether surgical removal is indicated based on the histological findings. MATERIALS AND METHODS: Between 1983 and 1997 a unilateral testicular nubbin consistent with a vanishing testis was excised in 29 patients an average of 28.6 months old. We retrospectively reviewed the gross pathology reports and microscopic slides, and prospectively performed histochemical stain analysis. RESULTS: Gross evaluation of the specimens revealed an identifiable cord structure in the majority of cases with the vas deferens most commonly identified in 72.4%. No recognizable testicular elements were present in any nubbin. In 3 cases the original pathology report identified cells with features consistent with Leydig cells, which immunohistochemical staining revealed to be atrophied cremasteric muscle fibers. CONCLUSIONS: In this series testicular nubbins in vanishing testes contained no viable testicular tissue. Since the risk of testicular cancer in an undescended testis is 8 to 10% and the incidence of viable testicular tissue in these nubbins ranges from 0% in our series to 11% in others, there is only a 0 to 1.1% risk of testicular cancer in the nubbin. Thus, surgical removal may not be warranted.

Abnormalities, Multiple↗

T-cell receptor zeta-chain expression on tumor-infiltrating lymphocytes from renal cell carcinoma.

Loss of the T-cell receptor-associated zeta chain in tumor-infiltrating lymphocytes (TILs) has been proposed as one mechanism of acquired immunosuppression in cancer patients. Recent reports suggest that zeta-chain loss may be related to contaminating monocyte/macrophage protease activity. Using flow cytometry and Western blot analysis, we have confirmed the expression of zeta chain in matched peripheral blood mononuclear cells and TILs from eight patients with primary renal cell carcinoma, when the cells were exposed to sufficient quantity of protease inhibitors. A small decrease in zeta-chain expression was found in three TIL samples. The loss of zeta-chain expression that was noted by others may be related to differences in laboratory method, and the small changes we have noted are unlikely to be sufficient in explaining the immunosuppression of TILs.

Biomarkers↗

Tissue-shrinkage correction factor in the calculation of prostate cancer volume.

Many studies that have calculated prostate cancer volumes from microscopic slides have used correction factors, ranging from 1.22 to 1.5, to compensate for tissue shrinkage during tissue processing. We undertook a study to measure tissue shrinkage directly because our experience suggested less shrinkage than that reported by others. Ten prostatectomy specimens were processed in a uniform manner. Multiple identical linear measurements were taken at four stages of processing: in the fresh state, following fixation, following processing, and from the microscopic slide. Linear shrinkage following fixation was minimal (4.1%) but increased to 14.5% following tissue processing. With rehydration and expansion on the flotation bath, tissues swelled so that net linear tissue shrinkage was 4.3%, and net volumetric tissue shrinkage was 12.4%, which translates into a correction factor for tissue shrinkage of 1.14. The following variables had no statistically significant effect on shrinkage: concentration of formalin, whole-mount versus quadrant sections, thickness of tissue slices, length of time in the alcohol dehydration steps, and temperature of the flotation bath over a range of 35 to 45 degrees C. This study suggests that (a) tissue-shrinkage correction factors that have been used in some previous studies may not be applicable for all laboratories because of interlaboratory variations in tissue-processing procedures or differences in measuring shrinkage; and (b) some calculated tumor volumes that have been used for prognostic thresholds may be high because of inflated tissue-shrinkage correction factors.

Humans↗

Corpus albicans-like structures in the gonads in androgen insensitivity syndrome.

The complete androgen insensitivity syndrome is the most common form of male pseudohermaphroditism and is due to end-organ unresponsiveness to androgens. The patients are phenotypically female, but the genotype is 46, XY, and the gonads are testicles. However, the common presence of Sertoli cell adenomalike nodules of immature seminiferous tubules and the frequent presence of stroma resembling ovarian stroma may cause confusion about the nature of the gonad. Herein, we report the occurrence in such a gonad of corpus albicans-like structures, which resulted from progressive hyalinization and aggregation of immature tubules. These structures, which to our knowledge have not been previously described, must be recognized for what they represent to avoid misinterpretation in the pathologic evaluation of this disorder.

Adult↗

Florid xanthomatous pelvic lymph node reaction to metastatic prostatic adenocarcinoma. A sequela of preoperative androgen deprivation therapy.

We describe a florid xanthomatous histiocytic reaction in the pelvic lymph nodes of a patient treated with androgen deprivation therapy prior to radical prostatectomy. The xanthomatous reaction was so marked that it nearly obscured the presence of metastatic carcinoma in the same lymph nodes. A similar histiocytic reaction was also present in association with carcinoma in the prostatectomy specimen, a finding that was not identified in pretreatment biopsy specimens. No other known cause of pronounced histiocytic lymph node proliferation was present in this patient. Only one brief description of a xanthomatous reaction in lymph nodes associated with this treatment has been previously recorded in the literature to our knowledge. Other patients from our institution who were treated similarly preoperatively all had lymph nodes negative for tumor, and none demonstrated a xanthomatous tissue reaction, suggesting that this reaction may be a marker for metastatic tumor in the same lymph node.

Adenocarcinoma↗

5-fluorouracil and allopurinol combined with recombinant interferon-alpha 2b in the treatment of patients with advanced prostate cancer: a phase I/II study.

PURPOSE: We determined the toxicity and preliminary response rate of escalating doses of 5-fluorouracil (670 to 1,500 mg./m.2 per day) combined with a fixed dose of interferon-alpha 2b (5 million units) and allopurinol (300 mg. every 8 hours) in cohorts of patients with metastatic prostate cancer. MATERIALS AND METHODS: The trial included 11 men with metastatic prostate cancer. Cohorts of patients received a 5-day constant infusion of 5-fluorouracil combined with subcutaneous interferon-alpha 2b 3 times weekly and allopurinol for 1 week during 5-fluorouracil infusion. Treatment was repeat every 3 weeks. RESULTS: Of 10 patients evaluable for treatment response and toxicity 3 had a partial response as judged by significant decreases in prostate specific antigen measurements (mean followup 13.5 months). Significant dose limiting toxicities encountered included mucositis, diarrhea and leukoneutropenia. CONCLUSIONS: Further evaluation of this treatment to determine overall response rates and benefit should take into consideration the significant toxicity experienced.

Aged↗

Fatal genitourinary mucormycosis in a patient with undiagnosed diabetes.

We present what we believe is the first report in the world literature of penile necrosis due to mucormycosis, a rare and often fatal fungal infection. This case of rhizopus mucormycosis began with a penile lesion in a 27-year-old patient with undiagnosed diabetes; it led to necrosis of the phallus, lower urinary tract, rectum, and pelvic musculature and finally to death. Despite repeated aggressive surgical debridement in conjunction with medical therapy, we were unable to halt the progression of the fungal and synergistic bacterial infections.

Adult↗

Acquired renal cystic disease and renal cell carcinoma in an allograft kidney.

Acquired renal cystic disease has been reported in the kidneys of patients with end stage renal disease who have been untreated, treated with dialysis or undergone renal transplantation. The incidence of renal tumor development in patients with acquired renal cystic disease is greater than 5% in those undergoing chronic hemodialysis. Recently, cases of renal cell carcinoma occurring with acquired renal cystic disease of the native kidneys of transplant recipients have been reported. Transplant patients have an increased incidence of malignancy when compared to the general population. Including our case, 19 cases of de novo renal neoplasms developing in renal allografts have been reported. To the best of our knowledge we report the longest interval to presentation of a de novo renal tumor in an allograft kidney (228 months) and the first case of renal cell carcinoma associated with acquired renal cystic disease in an allograft kidney.

Carcinoma, Renal Cell↗

Surgical treatment of verrucous carcinoma of the bladder unassociated with bilharzial cystitis: case report and literature review.

Verrucous carcinoma of the bladder unassociated with bilharzial cystitis is rare with only 6 cases reported to date. Verrucous carcinoma of the bladder, like that involving the cervix, vagina, oral cavity, perineum and lower extremities, may invade surrounding structures but remain surgically curable. Although it is similar to condyloma acuminatum, verrucous carcinoma is considered malignant because of its invasive growth pattern and it should be treated accordingly. However, no evidence of metastases has been noted to date. To our knowledge we report the first case of extravesical extension of verrucous carcinoma of the bladder that was treated successfully by surgical removal.

Carcinoma, Verrucous↗

Staging of prostate cancer with endorectal MR imaging: lessons from a learning curve.

Endorectal magnetic resonance (MR) imaging is the most accurate noninvasive method of staging prostate cancer. However, inexperienced radiologists may lack the necessary technical and interpretative skills to use this technique, and both radiologists and referring urologists may become frustrated with this method because of its inaccuracy compared with analysis of the radical prostatectomy specimen. Meticulous pathologic correlation is necessary to evaluate endorectal MR imaging findings. The authors compare their initial experience using endorectal MR imaging for staging prostate cancer (25 cases) with their later experience (25 cases) to highlight the various diagnostic pitfalls and "pearls" one may encounter when using endorectal MR imaging. Knowledge of the pathways of tumor spread inside and outside the gland may be helpful in interpreting endorectal MR images. The authors achieved a substantial improvement in the overall staging accuracy of endorectal MR imaging by careful pathologic correlation and by considering the anatomic features of prostate cancer.

Case-Control Studies↗